Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs), has announced two key appointments that signal its strategic focus on scaling operations and enhancing scientific leadership. Regina Donohue has been named Chief People Officer, and Suresh Durgam, M.D., has joined the company's Scientific Advisory Board (SAB). These moves come as Helus Pharma advances its pipeline toward potential commercialization, underscoring the company's commitment to building a robust infrastructure and expert guidance.
Donohue brings extensive human resources experience, most recently serving as Chief Human Resources Officer at Intra-Cellular, where she was instrumental in building the company's people strategy and infrastructure. During her tenure, she managed the company's growth to more than 1,000 employees as it transitioned into a commercial-stage organization. Notably, Intra-Cellular was acquired by Johnson & Johnson in April 2025, a testament to the successful scaling that Donohue helped drive. Her expertise in aligning HR practices with business goals will be crucial as Helus Pharma prepares for potential product launches.
Dr. Durgam, who also joins from Intra-Cellular, served as Executive Vice President and Chief Medical Officer, where he played a key role in securing FDA approvals for CAPLYTA across multiple indications. With over two decades of experience in CNS drug development, clinical development, medical affairs, regulatory strategy, and pharmacovigilance, Dr. Durgam will provide invaluable scientific guidance to Helus Pharma's SAB. His insights are expected to be particularly valuable as the company seeks to navigate the complexities of regulatory approval and commercial readiness.
Helus Pharma CEO Michael Halstead emphasized the importance of these appointments, stating that they strengthen the company's organizational capabilities and scientific leadership. As Helus Pharma advances its pipeline, which includes HLP003, a Phase 3 candidate for major depressive disorder with Breakthrough Therapy Designation, and HLP004, a Phase 2 candidate for generalized anxiety disorder, the company is positioning itself for future success by assembling a seasoned team.
The appointments reflect a broader trend in the biopharmaceutical industry where companies are investing in leadership and advisory expertise to navigate the path from clinical development to commercialization. For Helus Pharma, which operates in Canada, the United States, the United Kingdom, and Ireland, these strategic hires are likely to enhance its ability to execute on its mission of helping minds heal through innovative NSA therapies.
Investors and industry observers will be watching how these new team members contribute to Helus Pharma's progress. The company's focus on developing NSAs that promote neuroplasticity offers a novel approach to treating mental health conditions, and the addition of experienced leaders like Donohue and Durgam may increase confidence in the company's ability to deliver on its goals.
For more information on Helus Pharma and its developments, visit the company's newsroom at https://ibn.fm/HELP.
